A minority (6.3%) of participants experienced 1 or more hepatic adverse events, the most common being gamma glutamyl transferase increased (2.1%), alanine aminotransferase (ALT) increased (1.4%), aspartate aminotransferase increased (1.0%), hepatic enzyme increased (1.0%), and cholelithiasis (1.0%). The gene discussed is GPT; the disease is cholelithiasis.